



# Cardinal Health Inc. (CAH)

Updated May 6<sup>th</sup>, 2022, by Nathan Parsh

## Key Metrics

<b>Current Price:</b>	\$58	<b>5 Year CAGR Estimate:</b>	4.2%	<b>Market Cap:</b>	\$16.8 B
<b>Fair Value Price:</b>	\$52	<b>5 Year Growth Estimate:</b>	3.0%	<b>Ex-Dividend Date:</b>	06/30/22 <sup>1</sup>
<b>% Fair Value:</b>	112%	<b>5 Year Valuation Multiple Estimate:</b>	-2.2%	<b>Dividend Payment Date:</b>	07/15/22 <sup>1</sup>
<b>Dividend Yield:</b>	3.4%	<b>5 Year Price Target</b>	\$60	<b>Years Of Dividend Growth:</b>	34
<b>Dividend Risk Score:</b>	A	<b>Retirement Suitability Score:</b>	A	<b>Rating:</b>	Hold

## Overview & Current Events

Dublin, Ohio-based Cardinal Health is one of the “Big 3” drug distribution companies along with McKesson (MCK) and AmerisourceBergen (ABC). Cardinal Health serves over 24,000 United States pharmacies and more than 85% of the country’s hospitals. The company has operations in more than 30 countries with approximately 46,000 employees. With 34 years of dividend increases, the \$16.8 billion market cap company is a member of the Dividend Aristocrats Index.

On May 5<sup>th</sup>, Cardinal Health announced that its prior agreement to pay \$6 billion over 18 years in a national opioid settlement was finalized. More than 98% of lawsuits are included in this settlement.

Also on May 5<sup>th</sup>, 2022, Cardinal Health released Q3 fiscal 2022 results for the period ending March 31<sup>st</sup>, 2022 (Cardinal Health’s fiscal year ends June 30<sup>th</sup>). For the quarter, the company’s revenue grew 14.1% to \$44.8 billion, which was \$1.64 billion higher than expected. On an adjusted basis, the company posted earnings of \$545 million, or \$1.45 per share, compared to \$689 million, or \$1.53 per share, in the year ago period. Adjusted earnings-per-share was \$0.07 below estimates.

Pharmaceutical sales of \$41.4 billion was a 17% increase year-over-year, while segment profit of \$487 million was down 5%. Branded pharmaceuticals drove the revenue increase, but profit was down due to higher expenses and investments in technology. Revenue for the Medical segment decreased 7% to \$3.9 billion while segment profit decreased 66% to \$59 million. A divestiture was the main headwind to top-line decline. Inflationary pressures and supply chain constraints were a drag on profits. The Pharmaceutical segment makes up the lion’s share of revenues, but the Medical segment remains important due to its higher margins and growth potential.

Cardinal Health again updated its fiscal 2022 outlook, now anticipating \$5.15 to \$5.25 in adjusted EPS, from \$5.15 to \$5.50 and \$5.60 to \$5.90 previously.

## Growth on a Per-Share Basis

Year	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2027
<b>EPS</b>	\$3.21	\$3.73	\$3.84	\$4.38	\$5.24	\$5.40	\$5.00	\$5.28	\$5.45	\$5.57	<b>\$5.20</b>	<b>\$6.03</b>
<b>DPS</b>	\$0.88	\$1.09	\$1.25	\$1.41	\$1.61	\$1.81	\$1.86	\$1.91	\$1.93	\$1.94	<b>\$1.96</b>	<b>\$2.38</b>
<b>Shares<sup>2</sup></b>	343	340	337	328	322	316	309	298	294	294	<b>275</b>	<b>270</b>

In the 2011 through 2021 period, Cardinal Health has grown earnings-per-share by an average compound rate of 7.6% per year, while the dividend has grown at more than 9% annually. Moving forward we do not anticipate this sort of growth, especially considering the slowdown in earnings improvement in the last few years. After a disappointing end to fiscal 2021, Cardinal Health is expecting a decline for fiscal 2022.

We are forecasting 3% intermediate-term earnings growth, from management’s now lower guidance. Our subdued growth rate view could turn out to be conservative, especially with the company’s penchant for share repurchases. However, given the company’s earnings performance in 2016 through 2020, opioid litigation and a hot-topic drug pricing

<sup>1</sup> Estimated date.

<sup>2</sup> In millions.

Disclosure: This analyst has no position in the security discussed in this research report, and no plans to initiate one in the next 72 hours.



# Cardinal Health Inc. (CAH)

Updated May 6<sup>th</sup>, 2022, by Nathan Parsh

environment we are cautious for now. In addition, while the COVID-19 pandemic has helped results in the short-term, the long-term outlook remains quite uncertain.

Cardinal Health is holding up well in the pandemic, with elective procedures coming back and a material increase in personal protective equipment (PPE) demand.

## Valuation Analysis

Year	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	Now	2027
Avg. P/E	13.1	12.7	17.9	19.1	14.9	14.4	14.6	9.5	9.2	9.8	11.2	10.0
Avg. Yld.	2.1%	2.3%	1.8%	1.7%	2.1%	2.3%	2.9%	3.8%	3.8%	3.6%	3.4%	4.0%

Shares of Cardinal Health have increased 11.5% since our February 6<sup>th</sup>, 2022 report. The stock has traded hands with an average P/E ratio of 13.5 times earnings dating back to 2012. However, this was during a time when growth was much more robust. We have used a multiple of 10 times earnings as a starting place for fair value in recognition of our lower anticipated growth rate. Reaching our valuation target by 2027 would reduce annual returns by 2.2% over this period.

The dividend yield is now robust partly due to an expanding payout ratio, but mostly as a result of a lower share price in the last few years. While the pace of dividend growth has slowed, the starting yield is solid.

## Safety, Quality, Competitive Advantage, & Recession Resiliency

Year	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2027
Payout	27%	29%	33%	32%	31%	34%	37%	36%	35%	35%	38%	40%

Collectively the three major pharmaceutical wholesalers have a competitive advantage in the industry. Competition is held at bay by the massive scale already in place and the exceptionally low margins.


Cardinal Health has proven to be a solid operator in many ways – strong earnings for the past decade, a growing dividend and ample interest coverage. The dividend payout ratio had ticked up slightly in recent years, but its back to about a third of expected profits. In turn, the company has the ability to repurchase a meaningful number of shares.

As of the most recent report the company held \$2.4 billion in cash, \$30.9 billion in current assets, and \$42.1 billion in total assets against \$28.7 billion in current liabilities and \$42.1 billion in total liabilities. Long-term obligations stood at \$4.75 billion.

## Final Thoughts & Recommendation

Cardinal Health is projected to return 4.2% annually through 2027, down from 6.9% previously. Our forecast stems from a 3% growth rate and a 3.4% dividend yield, offset by a low single-digit headwind from multiple contraction. Cardinal Health has settled most of its opioid lawsuits, which should remove some of the overhang from the stock. That said, supply chain issues and inflationary pressure have caused the company to downwardly revise its guidance twice this fiscal year. We have lowered our five-year price target \$1 to \$60 and reiterate our hold rating on shares of Cardinal Health due to projected returns.

## Total Return Breakdown by Year



[Click here to rate and review this research report. Your feedback is important to us.](#)

Disclosure: This analyst has no position in the security discussed in this research report, and no plans to initiate one in the next 72 hours.



# Cardinal Health Inc. (CAH)

Updated May 6<sup>th</sup>, 2022, by Nathan Parsh

## Income Statement Metrics

Year	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021
<b>Revenue (\$B)</b>	107.5	101.1	91.18	102.5	121.5	130.0	136.8	145.5	152.9	162.5
<b>Gross Profit</b>	4541	4921	5161	5712	6543	6544	7181	6834	6868	6778
<b>Gross Margin</b>	4.2%	4.9%	5.7%	5.6%	5.4%	5.0%	5.2%	4.7%	4.5%	4.2%
<b>SG&amp;A Exp.</b>	2677	2875	3028	3240	3648	3775	4596	4480	4572	4533
<b>D&amp;A Exp.</b>	325	397	459	451	641	717	1032	1000	913	783
<b>Operating Profit</b>	1831	1888	1910	2191	2436	2242	1878	1733	1772	1794
<b>Operating Margin</b>	1.7%	1.9%	2.1%	2.1%	2.0%	1.7%	1.4%	1.2%	1.2%	1.1%
<b>Net Profit</b>	1069	334	1166	1215	1427	1288	256	1363	-3696	611
<b>Net Margin</b>	1.0%	0.3%	1.3%	1.2%	1.2%	1.0%	0.2%	0.9%	-2.4%	0.4%
<b>Free Cash Flow</b>	916	1532	2275	2240	2506	797	2384	2394	1585	2029
<b>Income Tax</b>	628	553	635	755	845	630	-487	386	-79	-289

## Balance Sheet Metrics

Year	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021
<b>Total Assets</b>	24260	25819	26033	30142	34122	40112	39951	40963	40766	44450
<b>Cash &amp; Equivalents</b>	2274	1901	2865	4616	2356	6879	1763	2531	2771	3407
<b>Acc. Receivable</b>	6355	6304	5380	6523	7405	8048	7800	8448	8264	9103
<b>Inventories</b>	7864	8373	8266	9211	10615	11301	12308	12822	13198	14590
<b>Goodwill &amp; Int.</b>	4392	5574	5870	6018	9426	9207	12229	11808	11275	10090
<b>Total Liabilities</b>	18016	19844	19632	23886	27551	33284	33892	34633	38974	42660
<b>Accounts Payable</b>	11726	12295	12149	14368	17306	17906	19677	21535	21374	23700
<b>Long-Term Debt</b>	2894	3854	3972	5492	5539	10395	9013	8031	6775	6236
<b>Total Equity</b>	6244	5975	6401	6256	6554	6808	6059	6328	1789	1791
<b>LTD/E Ratio</b>	0.46	0.65	0.62	0.88	0.85	1.53	1.49	1.27	3.79	3.48

## Profitability & Per Share Metrics

Year	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021
<b>Return on Assets</b>	4.5%	1.3%	4.5%	4.3%	4.4%	3.5%	0.6%	3.4%	-9.0%	1.4%
<b>Return on Equity</b>	17.7%	5.5%	18.8%	19.2%	22.3%	19.3%	4.0%	22.0%	-91.1%	34.1%
<b>ROIC</b>	12.2%	3.5%	11.5%	11.0%	12.0%	8.8%	1.6%	9.3%	-32.2%	7.4%
<b>Shares Out.</b>	343	340	337	328	322	316	309	298	294	294
<b>Revenue/Share</b>	308.17	293.88	264.01	306.06	368.32	406.18	434.31	483.50	521.92	552.61
<b>FCF/Share</b>	2.62	4.45	6.59	6.69	7.59	2.49	7.57	7.95	5.41	6.90

Note: All figures in millions of U.S. Dollars unless per share or indicated otherwise.

### Disclaimer

Nothing presented herein is, or is intended to constitute, specific investment advice. Nothing in this research report should be construed as a recommendation to follow any investment strategy or allocation. Any forward-looking statements or forecasts are based on assumptions and actual results are expected to vary from any such statements or forecasts. No reliance should be placed on any such statements or forecasts when making any investment decision. While Sure Dividend has used reasonable efforts to obtain information from reliable sources, we make no representations or warranties as to the accuracy, reliability or completeness of third-party information presented herein. No guarantee of investment performance is being provided and no inference to the contrary should be made. There is a risk of loss from an investment in marketable securities. Past performance is not a guarantee of future performance.